DEA Telehealth Prescribing Flexibilities Expire December 31, 2026
Six Weeks Out: What Practices Billing Controlled Substance Telehealth Visits Need to Fix Before the Cliff
Forty-six days. That's what stands between today and December 31, 2026, the date the DEA's fourth temporary extension of its telemedicine controlled substance prescribing flexibilities runs out. If your practice prescribes Schedule II through V medications, stimulants, benzodiazepines, buprenorphine for opioid use disorder, through a telehealth visit without a prior in-person exam, this isn't a background regulatory story. It's a countdown that affects whether a meaningful share of your patient panel can keep getting their medication the way they get it today.
The special registration framework that's supposed to make this temporary arrangement permanent has been in the works since January 2025 and is still sitting in White House review as of this writing. The DEA has said it intends to issue final regulations before the end of 2026, but "intends to" and "has finalized" are very different positions to be in with six weeks on the clock. Here's where things actually stand, what it costs your practice if the flexibility lapses, and what to do about it now instead of in the last week of December.
Where Things Actually Stand on November 16
The current rule traces back through a chain of temporary extensions that started during the COVID-19 public health emergency. The DEA and HHS issued their fourth extension on December 30, 2025, giving telemedicine prescribing flexibilities one more year, through December 31, 2026. That extension covers Schedule II through V controlled substances prescribed via telemedicine, and it applies uniformly across practitioner-patient relationships regardless of when the relationship started, it doesn't carve out a separate rule for new patients versus established ones.
The permanent fix was supposed to be a special registration framework, first proposed by the DEA in January 2025 after it drew more than 40,000 public comments, an unusually large response that signals how many prescribers and patients have a direct stake in the outcome. As proposed, it would create three distinct registration types: a standard telemedicine prescribing registration for Schedule III through V, an advanced registration for specialized clinicians prescribing Schedule II through V, and a platform registration for telehealth companies that facilitate prescribing. That proposed rule entered White House OMB review on August 25, 2026, and the Justice Department's own regulatory agenda had targeted November 2026 for further action. As of today, the DEA hasn't disclosed what the final rule actually contains, and multiple legal alerts tracking the process say its contents remain unknown even to close industry observers.
Separately, and already in effect, a final rule covering buprenorphine prescribing specifically took effect December 31, 2025. That rule requires synchronous audio-visual technology, not audio-only, for a qualifying telemedicine encounter and layers in its own practitioner registration requirements. If your practice treats opioid use disorder via telehealth, that piece of the puzzle isn't waiting on anything, it's already a live compliance requirement separate from the broader Schedule II-V extension.
What This Actually Costs a Practice If It Lapses
Run the numbers on your own telehealth panel before you assume this is someone else's problem. A behavioral health or pain management practice doing even 150 controlled-substance telehealth visits a month at an average reimbursement of $140 to $180 per visit is looking at roughly $21,000 to $27,000 a month in revenue tied directly to a prescribing pathway that could become unavailable on January 1. That's an illustration based on typical E/M-level telehealth reimbursement, not a guarantee for your specific payer mix, but it's the right order of magnitude to plan around, and it doesn't include the downstream cost of patients who simply stop treatment rather than schedule an in-person visit.
Opioid treatment programs and addiction medicine practices carry a second layer of exposure here, because the patients most dependent on telehealth access for buprenorphine and other medication-assisted treatment are often the same patients for whom an in-person visit requirement is the hardest barrier to clear: transportation, rural geography, work schedules, and the stigma that originally pushed a lot of OUD treatment toward telehealth in the first place. A disruption here isn't just a billing problem, it's a care-continuity problem that shows up in your no-show rate and your relapse-related utilization within a quarter, not just your next remittance advice.
- Behavioral health and psychiatry: stimulant prescriptions for ADHD management are Schedule II and among the most exposed if the flexibility lapses without a replacement.
- Addiction medicine and OTPs: buprenorphine telehealth visits already carry the December 31, 2025 audio-visual and registration requirements, on top of the broader Schedule II-V deadline.
- Pain management: any practice managing Schedule II or III pain medication through telehealth-only relationships should assume an in-person visit will be required if nothing changes by January 1.
The Compliance Risk Is Bigger Than a Billing Denial
It's worth being blunt about what's actually at stake if a practice keeps prescribing controlled substances via telehealth past a lapsed flexibility without the legally required in-person exam: that's not a coding error that gets caught in a clearinghouse edit, it's a potential violation of the Controlled Substances Act itself. The underlying requirement from the Ryan Haight Act, a prior in-person medical evaluation before prescribing a controlled substance, has never actually been repealed. The temporary extensions are what's been waiving it since the pandemic. If the extensions stop and no special registration framework replaces them, that in-person requirement doesn't need a new rule to come back into force, it just reverts to being the law a practice is already bound by.
State telehealth and controlled substance prescribing rules add another layer most practices underweight. A number of states impose their own in-person exam or telehealth registration requirements on top of whatever the DEA allows federally, which means "the DEA extended it" has never been a complete compliance answer by itself, you still need to check your state medical board and pharmacy board rules specifically. OIG's program integrity work has also flagged telehealth-prescribed controlled substances as an area of continuing audit interest, given the fraud schemes uncovered in prior telehealth prescribing crackdowns involving sham online platforms, and a practice with thin documentation of medical necessity for ongoing controlled substance telehealth prescribing is exactly the pattern auditors are primed to look for.
State rules don't wait on the DEA: a number of states layer their own in-person exam or telehealth registration requirements for controlled substance prescribing on top of whatever the federal flexibility allows. Confirm your state medical board and pharmacy board rules specifically rather than assuming a federal extension, or its lapse, is the whole compliance picture for your practice.
Your Action Plan Before December 31
Start with an honest inventory, not a policy memo: pull a list of every patient currently receiving a Schedule II through V prescription through a telehealth-only relationship, meaning no in-person visit has occurred since the prescribing relationship began. That list is your actual exposure, and it's the list you need regardless of what happens with the special registration rule, because even a favorable final rule is likely to come with its own registration and compliance steps that take time to implement, not an instant return to business as usual.
Next, build two tracks in parallel rather than betting everything on one outcome. Track one: for patients on your highest-risk list, specifically those on Schedule II medications with no in-person visit on file, start scheduling in-person exams now, before your December calendar fills with the same request from every other practice watching this deadline. Track two: if you treat OUD via telehealth, confirm your practice already meets the audio-visual and registration requirements from the buprenorphine final rule that took effect in December 2025, since that piece isn't contingent on what happens next, it's already active.
What to actually track between now and January 1
- A patient-level list of telehealth-only controlled substance prescribing relationships, sorted by schedule (II first) and by whether an in-person visit is already scheduled.
- The Federal Register and DEA's public announcements for the special registration final rule text, since the specific requirements it imposes, not just whether it exists, will determine your compliance workload.
- Your state medical board's own telehealth prescribing rules, independent of whatever the DEA finalizes federally.
- Documentation of medical necessity for every ongoing controlled substance prescription issued via telehealth, since that's the first thing a payer or state board audit will ask for regardless of how the federal rule shakes out.
None of this requires panic, but it does require starting now. A practice that waits for the DEA to finalize its rule before acting is choosing to compress six weeks of real scheduling and compliance work into whatever's left after the announcement actually lands.
Free Download: The 10-Point RCM Health Check
The billing gaps most practices don't catch until they show up as denials. Get the checklist: free, no spam.
✓ Got it! Your info is saved: view the checklist now →
We don't share your info. Unsubscribe any time.
Is Your Telehealth Prescribing Exposure Mapped Out?
Rcmaxis helps practices identify at-risk telehealth-only controlled substance patients and builds the billing and documentation trail that holds up if the rules shift again.
Get Your Free Revenue AssessmentFrequently Asked Questions About the DEA Telehealth Prescribing Deadline
When do the DEA telehealth prescribing flexibilities actually expire?
December 31, 2026. The DEA and HHS issued a fourth temporary extension in late December 2025 that runs through the end of 2026. Without a further extension or a finalized special registration rule, telemedicine prescribing of Schedule II through V controlled substances without a prior in-person exam is set to become prohibited starting January 1, 2027.
What is the DEA special registration rule and will it be ready in time?
The special registration framework, first proposed in January 2025, would create permanent telemedicine registration pathways so prescribers would not need to rely on temporary extensions. As of this writing it is still under White House OMB review, having entered that review on August 25, 2026, and the DEA has not confirmed its contents or guaranteed it will be finalized before the current flexibility expires.
Does the Ryan Haight Act still require an in-person exam before prescribing controlled substances by telehealth?
The underlying Ryan Haight Act requirement for a prior in-person medical evaluation has never been repealed. The temporary telemedicine flexibilities, extended repeatedly since the COVID-19 public health emergency, are what currently waive that requirement. If the flexibilities lapse without a replacement framework in place, the in-person exam requirement returns by default for new controlled substance prescriptions issued purely through telemedicine.
Related Resources
References
- Holland & Knight. DEA and HHS Extend Telemedicine Prescribing Flexibilities Through 2026. hklaw.com/insights/dea-and-hhs-extend-telemedicine-prescribing-flexibilities-2026
- Alliance for Connected Care, ConnectWithCare.org. DEA Prescribing of Controlled Substances: Days Until Fourth Extension Runs Out. connectwithcare.org/dea-prescribing-of-controlled-substances
- McDermott+ Consulting. DEA Appears Close to Finalizing Telemedicine Special Registration. mcdermottlaw.com/insights/dea-appears-close-to-finalizing-telemedicine-special-registration
- Frier Levitt. DEA Telemedicine Special Registration Final Rule Reaches White House Review. frierlevitt.com/dea-telemedicine-special-registration-final-rule-white-house-review
- Jones Day. DEA Releases Rules on Telemedicine Prescribing of Controlled Substances, Proposes Special Registrations. jonesday.com/insights/dea-releases-rules-telemedicine-prescribing-special-registrations
- U.S. Drug Enforcement Administration. Telemedicine. deadiversion.usdoj.gov/GDP
- Office of Inspector General, U.S. Department of Health and Human Services. OIG Work Plan. oig.hhs.gov/reports-and-publications/workplan
- Drug Enforcement Administration, Federal Register. Second Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Substances (public inspection document 2025-24123). public-inspection.federalregister.gov/2025-24123.pdf